Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time

Authors: Junliang Ma, Lunxu Liu, Guowei Che, Nanbin Yu, Fuqiang Dai, Zongbing You

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Tumor-associated macrophages (TAMs) play an important role in growth, progression and metastasis of tumors. In non-small cell lung cancer (NSCLC), TAMs' anti-tumor or pro-tumor role is not determined. Macrophages are polarized into M1 (with anti-tumor function) and M2 (with pro-tumor function) forms. This study was conducted to determine whether the M1 and M2 macrophage densities in NSCLC are associated with patient's survival time.

Methods

Fifty patients with an average of 1-year survival (short survival group) and 50 patients with an average of 5-year survival (long survival group) were included in this retrospective study. Paraffin-embedded NSCLC specimens and their clinicopathological data including up to 8-year follow-up information were used. Immunohistochemical double-staining of CD68/HLA-DR (markers for M1 macrophages) and CD68/CD163 (markers for M2 macrophages) was performed and evaluated in a blinded fashion. The M1 and M2 macrophage densities in the tumor islets, stroma, or islets and stroma were determined using computer-aided microscopy. Correlation of the macrophage densities and patient's survival time was analyzed using the Statistical Package for the Social Sciences.

Results

Approximately 70% of TAMs were M2 macrophages and the remaining 30% were M1 macrophages in NSCLC. The M2 macrophage densities (approximately 78 to 113 per mm2) in the tumor islets, stroma, or islets and stroma were not significantly different between the long survival and short survival groups. The M1 macrophage densities in the tumor islets (approximately 70/mm2) and stroma (approximately 34/mm2) of the long survival group were significantly higher than the M1 macrophage densities in the tumor islets (approximately 7/mm2) and stroma (13/mm2) of the short survival group (P < 0.001 and P < 0.05, respectively). The M2 macrophage densities were not associated with patient's survival time. The M1 macrophage densities in the tumor islets, stroma, or islets and stroma were positively associated with patient's survival time in a univariate analysis (P < 0.01 or 0.001). In a multivariate Cox proportional hazards analysis, the M1 macrophage density in the tumor islets was an independent predictor of patient's survival time.

Conclusions

The M1 macrophage density in the tumor islets is an independent predictor of survival time in NSCLC patients.
Appendix
Available only for authorised users
Literature
1.
Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest. 1997, 111 (6): 1710-1717. 10.1378/chest.111.6.1710.CrossRefPubMed
2.
Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66 (2): 605-612. 10.1158/0008-5472.CAN-05-4005.CrossRefPubMed
3.
Mantovani A, Sica A, Locati M: New vistas on macrophage differentiation and activation. Eur J Immunol. 2007, 37 (1): 14-16. 10.1002/eji.200636910.CrossRefPubMed
4.
Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P: Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005, 23 (35): 8959-8967. 10.1200/JCO.2005.01.4910.CrossRefPubMed
5.
Mantovani A, Sica A, Locati M: Macrophage polarization comes of age. Immunity. 2005, 23 (4): 344-346. 10.1016/j.immuni.2005.10.001.CrossRefPubMed
6.
Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Zembala M: Tumour-derived microvesicles modulate biological activity of human monocytes. Immunol Lett. 2007, 113 (2): 76-82. 10.1016/j.imlet.2007.07.014.CrossRefPubMed
7.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23 (11): 549-555. 10.1016/S1471-4906(02)02302-5.CrossRefPubMed
8.
Gordon S: Alternative activation of macrophages. Nat Rev Immunol. 2003, 3 (1): 23-35. 10.1038/nri978.CrossRefPubMed
9.
Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P: Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 2009, 33 (1): 118-126. 10.1183/09031936.00065708.CrossRefPubMed
10.
Yu N, Pu J, Pu Q, Che G, Zhang S, Liu L: Influence of Tumor Associated Macrophages Distribution on Prognosis of Non-small Cell Lung Cancer. Chin J Clin Thorac Cardiovasc Surg. 2009, 16 (1): 44-47.
11.
Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L: The origin and function of tumor-associated macrophages. Immunol Today. 1992, 13 (7): 265-270. 10.1016/0167-5699(92)90008-U.CrossRefPubMed
12.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 357 (9255): 539-545. 10.1016/S0140-6736(00)04046-0.CrossRefPubMed
13.
Chen JJ, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, Lee YC, Yang PC: Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003, 9 (2): 729-737.PubMed
14.
Toomey D, Smyth G, Condron C, Kelly J, Byrne AM, Kay E, Conroy RM, Broe P, Bouchier-Hayes D: Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up. Int J Cancer. 2003, 103 (3): 408-412. 10.1002/ijc.10836.CrossRefPubMed
15.
Ohno S, Inagawa H, Soma G, Nagasue N: Role of tumor-associated macrophage in malignant tumors: should the location of the infiltrated macrophages be taken into account during evaluation?. Anticancer Res. 2002, 22 (6C): 4269-4275.PubMed
16.
Kim DW, Min HS, Lee KH, Kim YJ, Oh DY, Jeon YK, Lee SH, Im SA, Chung DH, Kim YT, et al: High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer. 2008, 98 (6): 1118-1124. 10.1038/sj.bjc.6604256.CrossRefPubMedPubMedCentral
17.
Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, et al: Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008, 113 (6): 1387-1395. 10.1002/cncr.23712.CrossRefPubMed
18.
Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund LT: The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology. 2009, 55 (3): 301-312. 10.1111/j.1365-2559.2009.03379.x.CrossRefPubMed
19.
Geissmann F, Dieu-Nosjean MC, Dezutter C, Valladeau J, Kayal S, Leborgne M, Brousse N, Saeland S, Davoust J: Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med. 2002, 196 (4): 417-430. 10.1084/jem.20020018.CrossRefPubMedPubMedCentral
20.
Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoneda K, Imamura S, Schmitt D, Banchereau J: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med. 1996, 184 (2): 695-706. 10.1084/jem.184.2.695.CrossRefPubMed
21.
Nakamura H, Saji H, Aute I, Kawasaki N, Hosaka M, Ogata A, Saijo T, Kato H: Peripheral leukocytes with HLA-DR+/CD8- phenotype are associated with prognosis in patients with lung cancer. Anticancer Res. 2003, 23 (5b): 4149-4152.PubMed
22.
Maniecki MB, Moller HJ, Moestrup SK, Moller BK: CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology. 2006, 211 (6-8): 407-417. 10.1016/j.imbio.2006.05.019.CrossRefPubMed
Metadata
Title
The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time
Authors
Junliang Ma
Lunxu Liu
Guowei Che
Nanbin Yu
Fuqiang Dai
Zongbing You
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-112

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: Comparison of the CGH profiles between cancer cell lines and primary cancer tissues

Research article

Regulation of sonic hedgehog-GLI1 downstream target genes PTCH1, Cyclin D2, Plakoglobin, PAX6 and NKX2.2 and their epigenetic status in medulloblastoma and astrocytoma

Research article

Induction of cytotoxic T lymphocytes primed with Tumor RNA-loaded Dendritic Cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design

Research article

Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling

Research article

German cancer statistics 2004

Research article

Hypoxia induces differential translation of enolase/MBP-1
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits